Ulodesine

Overview

Ulodesine is a purine nucleoside phosphorylase ( PNP ) inhibitor, with an IC 50 of 2.293 nM against human PNP , and low nanomolar IC 50 values against mouse, rat and monkey PNP . Ulodesine blocks the production of uric acid precursors, reduces serum uric acid levels, clears accumulated uric acid in the blood, and elevates the levels of purine nucleosides including guanosine. Ulodesine reduces the counts of total lymphocytes, T lymphocytes and lymphocyte subsets, inhibits the proliferation of cancer cells and activated lymphocytes, and enhances vaccine immune responses. Ulodesine can be used in research related to hyperuricemia and gout.

Application

Products | Products > Disease Areas > Arthritis | Products > Disease Areas > Hyperuricemia | Products > Disease Areas > Gout | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Purine Metabolism | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Nucleoside Antimetabolite/Analog | Products > Signaling Pathways > Phosphatase

Product Information

• Catalog No.: HY-19480
• CAS No.: 548486-59-5
• Molecular Formula: C12H16N4O3
• Molecular Weight: 264.28
• Purity: 99.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1 mg/mL (3.78 mM); Clear solution
• Availability: In-stock

Source

Original product source